Full Press Release Details
Announces Third Quarter 2017 Results;
CGuard Revenue Increases 90% Versus Same Period Last year
Aviv, Israel-November 7, 2017 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in Embolic Prevention Systems (EPS)
/ thrombus management technologies and neurovascular devices, today announced preliminary results for the third quarter ending
Barry, PhD, Chief Executive Officer of InspireMD, commented, "Not only did we achieve a 90% year-over-year increase in sales
of CGuard EPS for the third quarter of 2017, but we also achieved a 22% sequential increase versus the second quarter of
2017. We achieved these strong results, even though the third quarter tends to be seasonally weak. We believe this growth is evidence
that our new distribution and key opinion leader strategy is working. We are hopeful that this growth will continue as the broader
community of mainstream vascular surgeons, interventional cardiologists, interventional neuroradiologists, and interventional
radiologists begin to adopt our technology. Given the safety advantages of the CGuard EPS, we believe that CGuard
has the potential to become the standard of care and to be regarded by physicians as a safer alternative to vascular surgery for
patients with carotid artery disease, thereby expanding the addressable market opportunity."
Barry continued, "We had several other notable accomplishments during the quarter. Most recently a live endovascular interventional
procedure featuring the CGuard EPS was transmitted real time at the Cracow Vascular Summit (CVS) 2017. The case was extremely
challenging, and CGuard EPS Carotid System performance was excellent. Additionally, patient enrollment began in an investigator
initiated trial in Russia, to assess the neuro protection and clinical superiority of the CGuard EPS versus Abbott's RX
ACCULINK Carotid Stent in subjects at high risk for Carotid Endarterectomy (CEA), a surgical procedure. Earlier in the second
quarter, we announced publication of an independent clinical review, authored by leading U.S. and European physicians supporting
the safety advantages of treating carotid artery disease with next generation carotid devices, specifically highlighting the CGuardTM
EPS clinical data compared to its competitors. We also announced that an endovascular interventional procedure featuring
the CGuard EPS was performed by two of the top key opinion leaders in Latin America and was broadcast at the SOLACI CACI
Congress of Cardiology 2017 in Buenos Aires. We believe these premier presentations, publications, and live clinical cases at
major clinical meetings further illustrate the growing interest and support for CGuard across Europe and around the world."
Barry concluded, "Operationally, we believe that the business looks very good as we continue to implement the strategy we
set out at the end of last year. We continue to grow our sales with our European distributors and are expanding our distribution
network globally. Several top key opinion leaders in Europe are embracing and advocating the CGuard EPS to their colleagues.
This is evident not only through their use of the product, but further illustrated by the testimonials we recently posted on our
website featuring leading clinicians from the fields of vascular surgery, interventional cardiology and interventional neuroradiology.
As a result, we remain hopeful CGuard EPS will in time become standard-of-care."
for the third quarter ended September 30, 2017 was $718,000 compared to $469,000 during the same period in 2016. The increase
was primarily due to an increase in sales of CGuard EPS as we continued focus on expanding existing markets such as Italy,
expansion into new geographies such as Russia as well as the transition from our prior exclusive distribution partner for most
of Europe to local distributors. Total operating expenses for the quarter ended September 30, 2017 were $2,238,000, an increase
of 25.2% compared to $1,788,000 for the same period in 2016. This increase was primarily due to an increase in sales and marketing
expenses to support the commercialization of CGuard EPS. Net loss for the quarter ended September 30, 2017 totaled $2,086,000,
or $0.19 per basic and diluted share, compared to a net loss of $1,995,000, or $0.85 per basic and diluted share, in the same
for the nine months ended September 30, 2017 was $1,927,000 compared to $1,572,000 during the same period in 2016. The increase
was primarily due to an increase in sales of CGuard EPS as we expanded into new geographies such as Russia, continued focus
on expanding existing markets such as Italy as well as the transition from our prior exclusive distribution partner for most of
Europe to local distributors. Total operating expenses for the nine months ended September 30, 2017 were $7,157,000, an increase
of 25.3% compared to $5,712,000 for the same period in 2016. This increase was primarily due to an increase in sales and marketing
expenses (primarily to support the commercialization of CGuard EPS), as well as an increase in salary expenses primarily
due to a salary related accrual. Net loss for the nine months ended September 30, 2017 totaled $6,939,000, or $0.87 per basic
and diluted share, compared to a net loss of $6,193,000, or $5.98 per basic and diluted share, in the same period in 2016.
of September 30, 2017, cash and cash equivalents were $4,765,000, compared to $7,516,000 as of December 31, 2016. Based on the
Company's current business plan, the Company believes its cash and cash equivalents as of September 30, 2017, will be sufficient
to meet its operating requirements up
to 4 months from the date of issuing these interim consolidated financial statements.
Company will host a conference call on Wednesday, November 8 at 8:00 a.m. Eastern Time. The conference call will be available
via telephone by dialing toll free 888-567-1602
for U.S. callers or +1 404-267-0373 for international
callers, or on the Company's Investor Relations section of the website: http://www.inspiremd.com/en/investors/investor-relations/.
webcast will also be archived on the Company's website and a telephone replay of the call will be available approximately
one hour following the call, through midnight November
22, 2017, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for
international callers and entering conference ID: 22280.
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection
and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization,
no reflow and major adverse cardiac events.
intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard ), neurovascular, and peripheral
artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants
are quoted on the NYSE American under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects," "predicts,"
"estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking
statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties
include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii)
negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for
the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v)
product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors
for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products,
(ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be
successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our
reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet
our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii)
the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations,
logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability
in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward
looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents
free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events or otherwise.
STATEMENTS OF OPERATIONS (1)
dollars in thousands, except per share data)
| Three months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenues | $ | 718 | $ | 469 | $ | 1,927 | $ | 1,572 | ||||||||
| Cost of revenues | 565 | 439 | 1,553 | 1,414 | ||||||||||||
| Gross Profit | 153 | 30 | 374 | 158 | ||||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | 288 | 289 | 1,041 | 946 | ||||||||||||
| Selling and marketing | 671 | 309 | 1,835 | 1,077 | ||||||||||||
| General and administrative | 1,279 | 1,190 | 4,281 | 3,689 | ||||||||||||
| Total operating expenses | 2,238 | 1,788 | 7,157 | 5,712 | ||||||||||||
| Loss from operations | (2,085 | ) | (1,758 | ) | (6,783 | ) | (5,554 | ) | ||||||||
| Financial expenses | 1 | 237 | 155 | 638 | ||||||||||||
| Loss before tax expenses | (2,086 | ) | (1,995 | ) | (6,938 | ) | (6,192 | ) | ||||||||
| Tax expenses (Income) | - | - | 1 | 1 | ||||||||||||
| Net Loss | $ | (2,086 | ) | $ | (1,995 | ) | $ | (6,939 | ) | $ | (6,193 | ) | ||||
| Net loss per share - basic and diluted | $ | (0.19 | ) | $ | (0.85 | ) | $ | (0.87 | ) | $ | (5.98 | ) | ||||
| Weighted average number of shares of common stock used in computing net loss per share - basic and diluted | 11,126,366 | 2,341,807 | 8,711,755 | 1,034,943 |
dollars in thousands)
| September 30, | December 31, | |||||||
| 2017 | 2016 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 4,765 | $ | 7,516 | ||||
| Accounts receivable: | ||||||||
| Trade, net | 538 | 356 | ||||||
| Other | 167 | 157 | ||||||
| Prepaid expenses | 109 | 65 | ||||||
| Inventory | 576 | 500 | ||||||
| Total current assets | 6,155 | 8,594 | ||||||
| Non-current assets: | ||||||||
| Property, plant and equipment, net | 495 | 379 | ||||||
| Funds in respect of employee rights upon retirement | 444 | 399 | ||||||
| Royalties buyout | 19 | 38 | ||||||
| Total non-current assets | 958 | 816 | ||||||
| Total assets | $ | 7,113 | $ | 9,410 |
| September 30, | December 31, | |||||||
| 2017 | 2016 | |||||||
| LIABILITIES AND EQUITY | ||||||||
| Current liabilities: | ||||||||
| Current maturity of long-term loan | $ | - | $ | 2,680 | ||||
| Accounts payable and accruals: | ||||||||
| Trade | 402 | 618 | ||||||
| Other | 2,293 | 1,447 | ||||||
| Advanced payment from customers | 28 | 33 | ||||||
| Total current liabilities | 2,723 | 4,778 | ||||||
| Long-term liabilities: | ||||||||
| Liability for employees rights upon retirement | 610 | 587 | ||||||
| Total long-term liabilities | 610 | 587 | ||||||
| Total liabilities | 3,333 | 5,365 | ||||||
| Equity: | ||||||||
| Common stock, par value $0.0001 per share; 150,000,000 shares authorized at September 30, 2017 and December 31, 2016; 7,465,889 and 1,475,318 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively | 1 | - | ||||||
| Preferred B shares, par value $0.0001 per share; 500,000 shares authorized at September 30, 2017 and December 31, 2016; 180,992 and 311,521 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively | - | - | ||||||
| Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at September 30, 2017; 743,213 shares issued and outstanding at September 30, 2017 | - | - | ||||||
| Additional paid-in capital | 142,632 | 135,959 | ||||||
| Accumulated deficit | (138,853 | ) | (131,914 | ) | ||||
| Total equity | 3,780 | 4,045 | ||||||
| Total liabilities and equity | $ | 7,113 | $ | 9,410 |
All 2017 financial information is derived from the Company's 2017 unaudited financial statements, as disclosed in the Company's
Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission, all 2016 financial information is derived from
the Company's 2016 unaudited financial statements, as disclosed in the Company's Quarterly Report on Form 10-Q, filed with the
Securities and Exchange Commission.
All September 30, 2017 financial information is derived from the Company's 2017 unaudited financial statements, as disclosed in
the Company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission. All December 31, 2016 financial
information is derived from the Company's 2016 audited financial statements as disclosed in the Company's Annual Report
on Form 10-K, for the twelve months ended December 31, 2016 filed with the Securities and Exchange Commission.